Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.61 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855425 | 0.80 | KDM4E (0.55) | L3MBTL1KDM4EALOX15TGFBR1METAP1 | |
| SCHEMBL24589754 | 0.79 | KMT2A (0.57) | L3MBTL1KDM4EMETAP1ALDH1A1NPC1 | |
| SCHEMBL14084546 | 0.79 | NPC1 (0.54) | L3MBTL1KDM4EMETAP1ALDH1A1CYP1A2 | |
| SCHEMBL3779006 | 0.79 | METAP1 (0.57) | L3MBTL1KDM4EALOX15TGFBR1METAP1 | |
| SCHEMBL5205380 | 0.78 | KDM4E (0.47) | ADORA2ANUDT1L3MBTL1KDM4EALOX15 | |
| SCHEMBL25430300 | 0.76 | KDM4E (0.51) | ADORA2AL3MBTL1KDM4EALOX15DCPS | |
| SCHEMBL29845663 | 0.76 | METAP1 (0.51) | L3MBTL1KDM4EALOX15METAP1ALDH1A1 | |
| SCHEMBL421987 | 0.76 | ADORA2A (1.00) | ADORA2ANUDT1DCPSALDH1A1CYP1A2 | |
| SCHEMBL3782688 | 0.76 | KDM4E (0.54) | L3MBTL1KDM4ETGFBR1METAP1ALDH1A1 | |
| SCHEMBL2179394 | 0.76 | RAB9A (0.47) | L3MBTL1KDM4ETGFBR1METAP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522872-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-3889254-B1 | A MEK1 MUTATION CONFERRING RESISTANCE TO RAF AND MEK INHIBITORS | DANA FARBER CANCER INST INC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240094208-A1 | MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11789022-B2 | MEK1 mutation conferring resistance to RAF and MEK inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220136057-A9 | METHODS OF IDENTIFYING RESPONSES TO MAP KINASE INHIBITION THERAPY | THE BROAD INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210404014-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-30 | — | — | US | disclosed |
| EP-3889254-A1 | A MEK1 MUTATION CONFERRING RESISTANCE TO RAF AND MEK INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20210277482-A1 | METHODS OF IDENTIFYING RESPONSES TO MAP KINASE INHIBITION THERAPY | THE BROAD INSTITUTE, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-11078540-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-10968484-B2 | Methods of identifying responses to map kinase inhibition therapy | THE BROAD INSTITUTE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2013169858-A1 | DIAGNOSTIC AND TREATMENT METHODS IN PATIENTS HAVING OR AT RISK OF DEVELOPING RESISTANCE TO CANCER THERAPY | THE BROAD INSTITUTE, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130143911-A1 | MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| EP-2580322-A1 | A MEK 1 MUTATION CONFERRING RESISTANCE TO RAF AND MEK INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20130059851-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2545187-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | Dana-Farber Cancer Institute Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120015973-A1 | MEK MUTATIONS CONFERRING RESISTANCE TO MEK INHIBITORS | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| EP-2370568-A1 | MEK MUTATIONS CONFERRING RESISTANCE TO MEK INHIBITORS | Dana-Farber Cancer Institute Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011112678-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010068738-A1 | MEK MUTATIONS CONFERRING RESISTANCE TO MEK INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2006137658-A1 | NEW SUBSTITUTED 1,3-THIAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING IMMUNOSUPPRESSION AND INFLAMMATION INHIBITORY ACITIVITY, INTERMEDIATE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONGBU HITEK CO., LTD. (KR) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220136057-A9 | METHODS OF IDENTIFYING RESPONSES TO MAP KINASE INHIBITION THERAPY | MAP3K5, MAP3K2, MAP3K4 | ADORA2A 4618/4885NUDT1 3439/4885L3MBTL1 3299/4885 |
| US-20210404014-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | CRKL, RAF1, TPX2 | ADORA2A 4829/4885NUDT1 3775/4885L3MBTL1 749/4885 |
| US-11789022-B2 | MEK1 mutation conferring resistance to RAF and MEK inhibitors | BRAF, RAF1, NRAS | ADORA2A 4660/4885NUDT1 1623/4885L3MBTL1 711/4885 |
| US-11078540-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | CRKL, RAF1, TPX2 | ADORA2A 4829/4885NUDT1 3775/4885L3MBTL1 749/4885 |
| US-20130059851-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | CRKL, RAF1, TPX2 | ADORA2A 4829/4885NUDT1 3775/4885L3MBTL1 749/4885 |
| US-20210277482-A1 | METHODS OF IDENTIFYING RESPONSES TO MAP KINASE INHIBITION THERAPY | MAP3K5, MAP3K2, MAP3K4 | ADORA2A 4618/4885NUDT1 3439/4885L3MBTL1 3299/4885 |
| US-10968484-B2 | Methods of identifying responses to map kinase inhibition therapy | MAP3K5, MAP3K2, MAP3K4 | ADORA2A 4618/4885NUDT1 3439/4885L3MBTL1 3299/4885 |
| US-20240094208-A1 | MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors | BRAF, RAF1, NRAS | ADORA2A 4713/4885NUDT1 3110/4885L3MBTL1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.